As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Aims and scope
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
COVID-19 and impact on peer review
EJNMMI Journal Family
Discover featured content, editor’s highlights, and the latest research via our Gateway to the EJNMMI Journal Family.
Annual Journal Metrics
39,5 days to first decision for reviewed manuscripts only
36,6 days to first decision for all manuscripts
93,1 days from submission to acceptance
24 days from acceptance to publication
115 Altmetric Mentions
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.
Check if your institution is a member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
Browse the journal's topical collections
The journal now offers Thematic Series related to a special topic. Browse the available list of collections or find out about the latest articles published for example in "Novel Theragnostic Drugs" or "PSMA Targeted Imaging and Therapy: Prostate and Other Cancers".
EJNMMI Research aims to be a platform of lively scientific exchange on new findings in basic, translational and clinical research in nuclear medicine and related matters. It addresses research in biology and medicine together with radiochemistry, radiopharmacy, radiophysics, dosimetry and instrumentation. The open access model speeds up the publication process and therefore favours rapid communication of new scientific results, even if still preliminary. Manuscripts are accepted for publication only after thorough peer review.
EJNMMI Research has been launched by Springer as a companion journal to the EJNMMI and not as a competitor. It offers space to authors whose manuscripts, despite high quality, cannot be accommodated by the EJNMMI. Consequently, authors of original manuscripts rejected by the EJNMMI are encouraged to submit their work to EJNMMI Research.
The journal also offers the possibility to publish reviews, short communications and selected case reports. Educational papers set out to improve and expand our understanding and knowledge in active research domains. Editorials and letters complete the exchange of views and ideas. We also welcome submission of well-designed studies that did not confirm the initial hypothesis, as we are convinced that they contribute to the advancement of science and should, therefore, be made available to the scientific community.
- ISSN: 2191-219X (electronic)